Egetis initiates rolling NDA for Emcitate

Egetis Therapeutics has started a rolling New Drug Application (NDA) to the US FDA for Emcitate (tiratricol) for the treatment of MCT8 deficiency. This follows a pre-NDA meeting on October 21 where the FDA confirmed eligibility based on available data and granted the rolling review process.

#biotech #FDA #MCT8 #Egetis